Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... inhibitors, 4.4% for nonnucleoside reversetranscriptase inhibitors, and 1.3% for nucleosidereversetranscriptase inhibitors. The frequency of multidrug resistance among the ... Research, Enzymes, Enzymology, HIV, Human Immunodeficiency Virus, Immunology, Protease Inhibitor, Protease Inhibitors, Proteins, Proteomics, Retrovirus, Reverse Transcriptase, Sexually ...
2009 NOV 9 ... lopinavir/ritonavir). Although resistance is a concern for patients taking non-nucleoside reverse transcriptase inhibitor-based regimens with imperfect adherence, virologic suppression can be achieved with less ...
2009 NOV 16 ... incidence of DSP, patients are more likely to become symptomatic following initiation of nucleoside reverse transcriptase inhibitor (NRTI) treatment," scientists writing in the journal Molecular Pain report. ...
2009 NOV 9 ... efavirenz or nevirapine; 41 of 338 (12.1%) had received tenofovir (TDF). The most common nucleoside reverse transcriptase inhibitor mutations observed were M184V (301, 89.1%) and K70R (91, 26.9%). The K65R mutation was ...
2009 NOV 23 ... reverse-transcriptase inhibitors (NNRTI), >= 3 primary protease inhibitor and nucleoside reverse transcriptase inhibitor (NRTI) mutations, and <= 3 darunavir and NNRTI mutations. The primary end point was ...
2009 NOV 16 ... "4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), a recently discovered nucleoside reverse transcriptase inhibitor, exhibits activity against a wide spectrum of wild-type and multidrug-resistant clinical ...
2009 NOV 16 ... or high genetic barrier regimen (with at Least one protease inhibitor [PI]) or non-nucleoside reverse transcriptase inhibitor or thymidine analogue) while a third non-thymidine nucleoside analogue was used in the ...
2009 NOV 16 ... "This RT-SHIVtc/macaque model could be suitable for the pre-clinical evaluation of non-nucleoside RT inhibitor-based anti-HIV microbicides." Jiang and colleagues published ... to recent research from the United States, "Human immunodeficiency virus type 1 (HIV-1) reversetranscriptase (RT) is a major target for antiretroviral strategy to block or curtail HIV ...
2009 NOV 16 ... "To review the pharmacology, pharmacokinetics, efficacy, and safety of apricitabine, a nucleoside reverse transcriptase inhibitor that is currently under investigation and has fast-track approval status with the Food ...
